Business
Vortex Announces Partnership with BioView
Vortex Announces Partnership with BioView.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 4851H NetScientific PLC 13 March 2018 \n\n \n \nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \n \nVortex Biosciences and BioView Announce Collaboration for Clinical Biomarker Identification on Circulating Tumor Cells\n \nLondon, UK - 13 March 2018 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, has announced a collaboration with BioView Ltd (TASE:BIOV), a provider of automated cell imaging and analysis solutions.\n \nThe collaboration will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact CTCs from blood samples to become part of the standard of care, with a view to increasing the prominence of CTCs in the clinical space as a diagnostic and monitoring tool. The aim of the collaboration is to provide clinicians with deeper insights into cancer biology. \n \nBioView (TLV: BIOV) is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. Bioview develops, manufactures and supplies cell imaging equipment, and analysis software to medical institutes and universities. It currently has several strategic collaborations with international scientific leaders and institutions. BioView's circulating tumour cell (CTC) application incorporates field-proven algorithms, developed in collaboration with leading cancer research centers worldwide.\n \nThe integrated VTX-1 and BioView workflow is currently being used in several clinical studies focused on CTC enumeration, ALK FISH rearrangements and PD-L1 expression on CTCs. PD-L1, in particular, has been a focus of the collaboration because of the potential clinical benefits. Overexpression of PD-L1 has been identified as a pathway that metastatic tumor cells use to evade immune detection.\n \nCommenting on the news, Francois Martelet, Chairman of Vortex BioSciences Inc. and CEO of NetScientific said: \"This partnership with BioView will allow automated identification of biomarkers expressed by CTCs collected by Vortex's platform. This technology has potential applications in the fast-evolving field of immuno-oncology and the collabo...